NanoViricides Inc. is moving forward with its development of Ebola and Dengue Fever vaccines, as well as other drug candidates, the company announced in its quarterly report on Friday.
The company recently signed an agreement with the U.S. Army Medical Institute of Infectious Diseases to continue testing potential Ebola vaccines. It is working quickly to develop its Ebola drug in response to the current epidemic in West Africa.
The company also acquired a new lab facility able to produce large quantities of Ebola vaccines. The original plan was to lease the facility from Inno-Haven LLC, but acquisition plans were made instead.
Current assets also will allow the company to spring forward to the initial human trials of DengueCide, a potential treatment for Dengue Fever.
Dengue Fever and Dengue Hemorrhagic Fever (DHF) are caused by viruses that are spread through mosquitoes. Symptoms include high fever, headaches, pain behind the eyes, mild bleeding, and joint, muscle and bone pain. In addition to Dengue fever symptoms, DHF is categorized by excessive vomiting, abdominal pain and difficulty breathing.
Resources also are in place to begin large animal safety and toxicology trials for NanoViricides' FluCide drug development program. High safety results in previous tests means the company is already performing scale up studies on FluCide.